Alk-Abelló A/S

ALK's peanut SLIT tablet shown safe & tolerable; phase II to evaluate efficacy, starting imminently. Trial completion expected in 2026.

ARS Pharmaceuticals' Form 10-Q report details financial performance: $2.1 million in revenue, $(21.7) million in operating loss, and $(19.1) million in net loss. neffy, a needle-free epinephrine product, was launched in the U.S. in September 2024, with regulatory approvals in the EU and plans for additional filings globally. The company faces challenges including market acceptance, regulatory approvals, and financial performance fluctuations.

ALK enters strategic license agreement with ARS Pharma for exclusive global rights to neffy® adrenaline nasal spray, excluding USA, Australia, New Zealand, Japan, and China. The deal supports ALK's Allergy+ strategy and long-term financial goals, with potential for new indications like acute urticaria. ALK to pay USD 145 million upfront plus future milestones and royalties.